Why the study?
Does semuloparin reduce thromboembolic events in patients receiving chemotherapy for cancer?
Does semuloparin reduce thromboembolic events in patients receiving chemotherapy for cancer?
Semuloparin provides effective thromboprophylaxis without increasing major bleeding in cancer patients undergoing chemotherapy.
Answers are grounded in this paper and cite their sources.
Supports thromboprophylaxis consideration during cancer chemotherapy; confirms net benefit in a dedicated RCT.
Semuloparin reduces the incidence of thromboembolic events in patients receiving chemotherapy for cancer, with no apparent increase in major bleeding. (Funded by Sanofi; ClinicalTrials.gov number, NCT00694382.).
No takes yet. Share an insight, caveat, or question.
Agnelli et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: